Financing of diagnostics and personalised medicine start-ups to create synergies with Debiopharm Group
The objective of Debioinnovation is to add synergies to the core drug development expertise and business focus of Debiopharm Group, through the financing of biotech start-up companies. Adjacent and related technologies such as companion diagnostics, biomarker development and large molecule capabilities are particular areas of interest.
Debioinnovation aims at investing into two to three companies per year, with a capital participation in each company not to exceed 25%, and with representation on the Board of Directors.
Milestones
To this date, the Company has invested in nine companies, including Eclosion, NeoVacs, TcLand Expression, Effimune, Biocartis, Diagnoplex, Agendia, Immunexpress and Spinomix.
Management
 |
Rolland-Yves MauvernayPresident and Founder, Debiopharm Group™ |
Dr Mauvernay completed his medical studies at the Faculty of Medicine and Pharmacy at the University of Strasbourg, France and later obtained his Ph.D. in Biology, Bacteriology and Pharmacy. In 1953, he established RIOM Laboratories, in Auvergne, France and purchased several pharmaceutical laboratories and various rare molecules. In 1973, he sold RIOM and in 1979, founded Debiopharm SA, a biopharmaceutical development company which fully funds and develops innovative therapeutics. He later created Debio R.P. SA, specialising in the development of sustained-release advanced drug delivery systems and manufacturing. In 1993, he founded Debioclinic SA, a clinical research organisation in Paris.
Today, Dr Mauvernay heads a group of 300 employees, supported by 500 external experts, who are responsible for research and development.
 |
Thierry MauvernayDelegate of the Board, Debiopharm Group™ |
Mr. Mauvernay received his Master of Science in Economics in 1975. He then obtained a degree from the 'Institut d'Administration des Entreprises’ and a ‘Diplôme d'Études Supérieures Spécialisées en Marketing’ in Clermont-Ferrand, France in 1976. In 1978, he founded an international cosmetics company, which he later sold but continued to manage until July 2001, when he joined Debiopharm SA as Executive Vice President with direct responsibilities for the Finance and Administration Department. In 2006, Mr Mauvernay handed over his operational activities within Debiopharm SA and has since been focusing on the administration, finance and strategy of Debiopharm Group.
